



Obstructive Airway Disease




Dr. Khalid Al-Mobaireek
King Khalid University Hospital

Obstructive airway Disease:

- Physiological:
 - Reversible = Asthma
 - Irreversible: Bronchiectasis
- Anatomical:
 - Upper
 - Lower




Inspiration




Expiration

Types Of Stridor And Probable Site of Obstruction




Bronchiectasis

- Localized:
 - Anatomical
 - Airway: Internal, External,
 - Parynchymal
- Diffuse:
 - Aspiration
 - Mucociliary clearance: PCD, CF
 - Immune deficiency
 - Congenital
 - Post-infectious: Pertusis, TB, adenovirus..







Normal



**Both
Arms
Absent**



**Absent
ODA**



**Absent
IDA**

Nose cilia cross-section







Image:
A. Shoemark









Definition of Asthma

- A chronic **inflammatory** disorder of the airways
- Many cells and cellular elements play a role
- Chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing
- Widespread, variable, and often reversible airflow limitation




Bronchospasm
Edema, Mucus

Hyperresponsiveness

INFLAMMATION

Asthma Inflammation: Cells and Mediators



Asthma Inflammation: Cells and Mediators

Inflammatory cells

Mast cells
Eosinophils
Th2 cells
Basophils
Neutrophils
Platelets

Structural cells

Epithelial cells
Sm muscle cells
Endothelial cells
Fibroblast
Nerves



Mediators

Histamine
Leukotrienes
Prostanoids
PAF
Kinins
Adenosine
Endothelins
Nitric oxide
Cytokines
Chemokines
Growth factors



Effects

Bronchospasm
Plasma exudation
Mucus secretion
AHR
Structural changes







NORMAL




ASTHMA




Healthy Airway




Asthmatic Airway



AIR TRAPPING



Ventilation Perfusion (V/Q) Mismatch





Burden of Asthma


- Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals
- Prevalence increasing in many countries, especially in children
- A major cause of school/work absence


Asthma Prevalence



10 - 15%

Asthma Prevalence





Qaseem 13%

Khobar 6%

Riyadh 10%

Jeddah 13%

Abha 17%



Factors that Influence Asthma Development and Expression

Host Factors

- Genetic
 - Atopy
 - Airway hyperresponsiveness
- Gender
- Obesity

Environmental Factors


- Indoor allergens
- Outdoor allergens
- Occupational sensitizers
- Tobacco smoke
- Air Pollution
- Respiratory Infections
- Diet

Environmental Allergens and Childhood Asthma

- Dust mites
- Furry pets
- Molds
- Cockroaches
- **Cigarette
Smoking**



POLLENS



Management of Chronic Asthma

History

- Symptoms (cough, wheeze, SOB)
- Onset, duration, frequency and severity
- Activity and nocturnal exacerbation
- Previous therapy
- Triggers
- Other atopies
- Family history
- Environmental history, SMOKING
- Systemic review





Physical Examination

- Growth parameter
- ENT
- Features of atopy
- Chest findings
- PEF

Investigations

- Pulmonary Function Test
- Chest X ray in some.
- Allergy testing in some





Skin Testing


Differential Diagnosis

- Recurrent aspiration
- Bronchiolitis
- Cardiac failure
- Bronchopulmonary Dysplasia
- Inhaled foreign body
- Bronchiectasis
- Gastroesophageal Reflux
- Primary Ciliary Dyskinesia
- Cystic Fibrosis
- Vocal cord dysfunction/
Hyperventilation
- Structural anomalies:
Tracheomalacia/
Bronchomalacia..etc.

FORCED
EXPIRATION




SUPINE
AP





Levels of Asthma Control

<i>Characteristic</i>	Controlled (All of the following)	Partly controlled (Any present in any week)	Uncontrolled
Daytime symptoms	None (2 or less / week)	More than twice / week	3 or more features of partly controlled asthma present in any week
Limitations of activities	None	Any	
Nocturnal symptoms / awakening	None	Any	
Need for rescue / “reliever” treatment	None (2 or less / week)	More than twice / week	
Lung function (PEF or FEV₁)	Normal	< 80% predicted or personal best (if known) on any day	
Exacerbation	None	One or more / year	



REDUCE

INCREASE

TREATMENT STEPS

	STEP 1	STEP 2	STEP 3	STEP 4	STEP 5
	asthma education				
	environmental control				
	as needed rapid-acting β_2 -agonist	as needed rapid-acting β_2 -agonist			
CONTROLLER OPTIONS		SELECT ONE	SELECT ONE	ADD ONE OR MORE	ADD ONE OR BOTH
		low-dose ICS*	low-dose ICS <i>plus</i> long-acting β_2 -agonist	medium- <i>or</i> high-dose ICS <i>plus</i> long-acting β_2 -agonist	oral glucocorticosteroid (lowest dose)
		leukotriene modifier**	medium- <i>or</i> high-dose ICS	leukotriene modifier	anti-IgE treatment
			low-dose ICS <i>plus</i> leukotriene modifier	sustained-release theophylline	
			low-dose ICS <i>plus</i> sustained-release theophylline		

*inhaled glucocorticosteroids

** receptor antagonist or synthesis inhibitors



Treatment objectives

- Achieve and maintain control of symptoms
- Maintain normal activity levels, including exercise
- Maintain pulmonary function as close to normal levels as possible
- Prevent asthma exacerbations
- Avoid adverse effects from asthma medications
- Prevent asthma mortality

Treatment strategy

1. Develop Patient/Doctor Partnership
2. Identify and Reduce Exposure to Risk Factors
3. Assess, Treat and Monitor Asthma
4. Manage Asthma Exacerbations
5. Special Consideration

Pharmacological therapy

■ Relievers

- Inhaled fast-acting β_2 -agonists
- Inhaled anticholinergics

■ Controllers

- Inhaled corticosteroids
- Inhaled long-acting β_2 -agonists
- Inhaled cromones
- Oral anti-leukotrienes
- Oral theophyllines
- Oral corticosteroids

Why don't patients comply with treatment?

Intentional

- Feel better
- Fear of side effects
- Don't notice any benefit
- Fear of addiction
- Fear of being seen as an invalid
- Too complex regimen
- Can't afford medication

Unintentional

- Forget treatment
- Misunderstand regimen / lack information
- Unable to use their inhaler
- Run out of medication

Cromolyn Sodium


- Non-steroidal anti-inflammatory
- Weak action on Early and late phases
- Slow onset of action
- If no response in 6 weeks change to ICS
- Side effects: Irritation




Amni Visnaga, also known as khellin, from which the cromone for DSCG was derived


Inhaled Corticosteroids

- Effective in most cases
- Safe especially at low doses
- The anti-inflammatory of choice in asthma





Asthmatic



Steroid-treated asthmatic

Inhaled Steroids

Side Effects

- Growth: No significant effect at low to moderate doses.
- Bones: not important
- HPA axis: No serious clinical effect (high doses)
- Alteration of glucose and lipid metabolism: Clinical significant is unclear (high doses)
- Cataract: No increase risk
- Skin: Purpura, easily bruising, dermal thinning
- Local side effects

Nebulizers



MDI and spacer



Dry powder inhalers



MANAGEMENT OF ACUTE ASTHMA

Assessment: History

- Symptoms
- Previous attacks
- Prior therapy
- Triggers

Physical examination:

Signs of airway obstruction:

- **Fragmented speech**
- **Unable to tolerate recumbent position**
- **Expiration > 4 seconds**
- **Tachycardia, tachypnea and hypotension**
- **Use of accessory muscles**
- **Pulsus paradoxus > 10 mmhg**
- **Silent hyperinflated chest**
- **Air leak**

Physical examination:

Signs of tissue hypoxia:

- Cyanosis
- Cardiac arrhythmia and hypotension
- Restlessness, confusion, drowsiness and obtundation

Physical examination:

Signs of Respiratory muscles fatigue:

- Increase respiratory rate
- Respiratory alterans (alteration between thoracic and abdominal muscles during inspiration)
- Abdominal paradox (inward movement of the abdomen during inspiration)

Investigations:

- Peak expiratory flow rate
- Pulse oxymetry
- ABG



- CXR



ONLY IN FEW CASES

The First Hour

Oxygen

- Hypoxemia is common
- It worsens airway hyperreactivity
- Monitor saturation

Inhaled β_2 agonist

Every 20 minutes in the first hour
Assess after each nebulizer




Steroids

- If not responding to the β agonist
- If severe in the beginning
- If on PO prednisone or high dose inhaled steroids.
- Previous severe attacks

Ipratropium Bromide

- **Anti-cholinergic**
- **For severe cases**
- **Along with β 2 agonist**

Response to the first hour



Discharge

- Follow up
- Give inhaled β_2 agonist
- Steroids
- When to come back?